Syngene International Limited

NSEI:SYNGENE Rapporto sulle azioni

Cap. di mercato: ₹334.7b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Syngene International Gestione

Gestione criteri di controllo 2/4

Syngene International's Il CEO è Jonathan Hunt, nominato in Jan2016, e ha un mandato di 8.58 anni. la retribuzione annua totale è ₹ 285.33M, composta da 50% di stipendio e 50% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.062% delle azioni della società, per un valore di ₹ 204.41M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 7.5 anni e 6 anni.

Informazioni chiave

Jonathan Hunt

Amministratore delegato

₹285.3m

Compenso totale

Percentuale dello stipendio del CEO50.0%
Mandato del CEO8.6yrs
Proprietà del CEO0.06%
Durata media del management7.5yrs
Durata media del Consiglio di amministrazione6yrs

Aggiornamenti recenti sulla gestione

Recent updates

Syngene International Limited's (NSE:SYNGENE) Popularity With Investors Is Under Threat From Overpricing

Jul 16
Syngene International Limited's (NSE:SYNGENE) Popularity With Investors Is Under Threat From Overpricing

These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely

Mar 28
These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely

Do Syngene International's (NSE:SYNGENE) Earnings Warrant Your Attention?

Feb 14
Do Syngene International's (NSE:SYNGENE) Earnings Warrant Your Attention?

Earnings Not Telling The Story For Syngene International Limited (NSE:SYNGENE)

Jan 19
Earnings Not Telling The Story For Syngene International Limited (NSE:SYNGENE)

Is Syngene International (NSE:SYNGENE) A Risky Investment?

Nov 19
Is Syngene International (NSE:SYNGENE) A Risky Investment?

Is Now The Time To Put Syngene International (NSE:SYNGENE) On Your Watchlist?

Nov 01
Is Now The Time To Put Syngene International (NSE:SYNGENE) On Your Watchlist?

Syngene International (NSE:SYNGENE) Seems To Use Debt Rather Sparingly

Aug 07
Syngene International (NSE:SYNGENE) Seems To Use Debt Rather Sparingly

These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely

Apr 28
These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely

Here's Why We Think Syngene International (NSE:SYNGENE) Is Well Worth Watching

Apr 06
Here's Why We Think Syngene International (NSE:SYNGENE) Is Well Worth Watching

Does Syngene International (NSE:SYNGENE) Deserve A Spot On Your Watchlist?

Jan 04
Does Syngene International (NSE:SYNGENE) Deserve A Spot On Your Watchlist?

Syngene International (NSE:SYNGENE) Has A Pretty Healthy Balance Sheet

Dec 08
Syngene International (NSE:SYNGENE) Has A Pretty Healthy Balance Sheet

Is Syngene International (NSE:SYNGENE) Using Too Much Debt?

Aug 28
Is Syngene International (NSE:SYNGENE) Using Too Much Debt?

Syngene International Limited (NSE:SYNGENE) Shares Could Be 22% Above Their Intrinsic Value Estimate

Aug 10
Syngene International Limited (NSE:SYNGENE) Shares Could Be 22% Above Their Intrinsic Value Estimate

These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Reasonably Well

May 10
These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Reasonably Well

Does Syngene International (NSE:SYNGENE) Have A Healthy Balance Sheet?

Feb 02
Does Syngene International (NSE:SYNGENE) Have A Healthy Balance Sheet?

Does Syngene International (NSE:SYNGENE) Deserve A Spot On Your Watchlist?

Nov 26
Does Syngene International (NSE:SYNGENE) Deserve A Spot On Your Watchlist?

Here's Why Syngene International (NSE:SYNGENE) Can Manage Its Debt Responsibly

Sep 21
Here's Why Syngene International (NSE:SYNGENE) Can Manage Its Debt Responsibly

Here's Why I Think Syngene International (NSE:SYNGENE) Is An Interesting Stock

Aug 06
Here's Why I Think Syngene International (NSE:SYNGENE) Is An Interesting Stock

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Jonathan Hunt rispetto agli utili di Syngene International?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

₹5b

Mar 31 2024₹285m₹143m

₹5b

Dec 31 2023n/an/a

₹5b

Sep 30 2023n/an/a

₹5b

Jun 30 2023n/an/a

₹5b

Mar 31 2023₹85m₹85m

₹5b

Dec 31 2022n/an/a

₹4b

Sep 30 2022n/an/a

₹4b

Jun 30 2022n/an/a

₹4b

Mar 31 2022₹76m₹76m

₹4b

Dec 31 2021n/an/a

₹4b

Sep 30 2021n/an/a

₹4b

Jun 30 2021n/an/a

₹4b

Mar 31 2021₹65m₹65m

₹4b

Dec 31 2020n/an/a

₹4b

Sep 30 2020n/an/a

₹4b

Jun 30 2020n/an/a

₹4b

Mar 31 2020₹66m₹66m

₹4b

Dec 31 2019n/an/a

₹4b

Sep 30 2019n/an/a

₹4b

Jun 30 2019n/an/a

₹3b

Mar 31 2019₹90m₹47m

₹3b

Dec 31 2018n/an/a

₹3b

Sep 30 2018n/an/a

₹3b

Jun 30 2018n/an/a

₹3b

Mar 31 2018₹94m₹47m

₹3b

Compensazione vs Mercato: La retribuzione totale di Jonathan ($USD 3.40M ) è superiore alla media delle aziende di dimensioni simili nel mercato Indian ($USD 591.43K ).

Compensazione vs guadagni: La retribuzione di Jonathan è aumentata di oltre il 20% nell'ultimo anno.


AMMINISTRATORE DELEGATO

Jonathan Hunt (55 yo)

8.6yrs

Mandato

₹285,330,000

Compensazione

Mr. Jonathan Brittan Hunt serves as the Managing Director of Syngene International Limited since April 1, 2020. He has been the Chief Executive Officer of Syngene International Ltd. since January 2016 and...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Jonathan Hunt
MD, CEO & Executive Director8.6yrs₹285.33m0.062%
₹ 206.7m
Sibaji Biswas
CFO & Executive Director4.7yrs₹34.14m0.017%
₹ 56.8m
Krishnan G
Head of Investor Relationsno dataNessun dato0.0028%
₹ 9.4m
Priyadarshini Mahapatra
Head of Legal5.1yrs₹4.72m0.0024%
₹ 8.0m
Sandeep Nair
Head of Corporate Communicationsno dataNessun datoNessun dato
Andrew Webster
Chief Human Resources Officer1.7yrsNessun datoNessun dato
Dhananjay Patankar
Head of Pharmaceutical & Biopharmaceutical Developmentno data₹10.80mNessun dato
Purushottam Singnurkar
Head of Formulations Developmentno data₹5.50m0.025%
₹ 83.3m
Ajit Manocha
Head of IT8.5yrsNessun dato0.0029%
₹ 9.7m
Jayashree Aiyar
Head of Discovery Biology8.6yrsNessun dato0%
₹ 0
Chetan Tamhankar
Head of Clinical Development & Stability Studies8.6yrsNessun dato0.0040%
₹ 13.5m
Rajendra Patil
Head of EHSS6.6yrsNessun dato0.0093%
₹ 31.3m

7.5yrs

Durata media

Gestione esperta: Il team dirigenziale di SYNGENE è esperto e expertise (durata media dell'incarico 7.5 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Jonathan Hunt
MD, CEO & Executive Director7.3yrs₹285.33m0.062%
₹ 206.7m
Sibaji Biswas
CFO & Executive Directorless than a year₹34.14m0.017%
₹ 56.8m
Catherine Rosenberg
Non-Executive Director24yrs₹8.28m0.0022%
₹ 7.3m
Kiran Mazumdar-Shaw
Non-Executive Chairpersonno data₹9.43m0.0055%
₹ 18.3m
Vinita Bali
Lead Independent Director7.1yrs₹8.62mNessun dato
Vijay Kuchroo
Independent Director7.4yrs₹7.46m0.012%
₹ 41.7m
Nilanjan Roy
Additional Independent Directorless than a yearNessun datoNessun dato
Kush Parmar
Independent Non Executive Director3.2yrs₹6.47mNessun dato
Paul Blackburn
Non-Executive Independent Director10yrs₹9.12m0.012%
₹ 41.7m
Manja Boerman
Independent Directorless than a yearNessun datoNessun dato
Sharmila Karve
Additional Independent Director5yrs₹8.46mNessun dato

6.0yrs

Durata media

63yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di SYNGENE sono considerati esperti (durata media dell'incarico 6 anni).